BACKGROUND: Structural left ventricular remodeling after @entity583 is a complex process with several pathophysiologic descriptors that can be modified by pharmacotherapy. However, the possibility that different classes of antiremodeling agents might exert different effects on different remodeling parameters after reperfused and nonreperfused @entity583 has not been systematically studied. METHODS AND RESULTS: We measured detailed left ventricular remodeling parameters in vivo (echocardiograms) repeatedly over 6 weeks and ex vivo (planimetry) at 6 weeks after @entity583 in 36 @entity235 randomized (factorial design) after reperfused or nonreperfused @entity583 to 6 weeks of twice daily oral therapy with the @entity460 channel blocker @entity3591 (5 mg), the angiotensin-converting enzyme inhibitor @entity4688 (5 mg) or placebo, and 18 matching sham or control animals. Compared to placebo and control groups over 6 weeks, both agents reduced left ventricular loading and limited overall remodeling in both reperfused and nonreperfused groups, but there were pertinent differences. @entity4688 limited the increase in left @entity67 in the reperfused group. Both @entity4688 and @entity3591 limited @entity1188 zone thinning in the nonreperfused groups but increased @entity1188 zone thinning in the reperfused groups, despite preserved @entity1188 zone collagen with @entity3591 . @entity4688 decreased left ventricular diastolic volume and mass more than @entity3591 in the reperfused group and increased left ventricular ejection fraction in the nonreperfused group. Both agents limited regional and global shape deformation in reperfused and non-reperfused groups. Diastolic wall stress in the @entity1188 zone decreased with @entity3591 , and increased with @entity4688 and reperfusion. CONCLUSIONS: Different antiremodeling therapies may exert different effects on different remodeling parameters during healing after reperfused @entity583 . Significant interactions occur during reperfusion. More than one variable may be needed for the comprehensive assessment of the antiremodeling efficacy of different therapies.

Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused XXXX : different effects on different parameters.

@entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril', 'Enalapril'] @entity235 :: ('9615', 'Species') :: ['dogs'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular asynergy']
@entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']
